Explore the words cloud of the BETA3_LVH project. It provides you a very rough idea of what is the project "BETA3_LVH" about.
The following table provides information about the project.
Coordinator |
UNIVERSITE CATHOLIQUE DE LOUVAIN
Organization address contact info |
Coordinator Country | Belgium [BE] |
Project website | http://www.beta3lvh.eu/ |
Total cost | 5˙425˙112 € |
EC max contribution | 5˙425˙112 € (100%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-PHC-2014-two-stage |
Funding Scheme | RIA |
Starting year | 2015 |
Duration (year-month-day) | from 2015-05-01 to 2020-04-30 |
Take a look of project's partnership.
Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fraction (HFpEF), a highly prevalent disease in the elderly, mostly women population. There is currently no specific, defined treatment for HFpEF, beyond control of risk factors. Activation of cardiac and vascular Beta3-adrenergic receptors (B3AR) represents a new concept and a novel target for structural cardiac disease. B3AR expression and coupling were demonstrated in human myocardium and vasculature. In pre-clinical models with expression of the human receptor, its activation attenuates myocardial remodelling, i.e. decreases hypertrophy and fibrosis in response to neurohormonal or hemodynamic stress. Mirabegron is a new agonist of B3AR available for human use, that was recently introduced for a non-cardiovascular indication (overactive bladder disease). The primary objective of the project is to design and implement a multi-centric, prospective, randomized, placebo-controlled clinical trial testing the additional beneficial effect of mirabegron, versus placebo over 12 months on top of standard treatment of patients carrying structural cardiac disease without overt heart failure (stage B of AHA classification); the co-primary end-point will be the quantitative change in myocardial hypertrophy measured by cardiac MRI; and in diastolic ventricular function, measured by Doppler echocardiography (E/E’); in addition, exercise tolerance (peak VO2) will be measured as well as circulating biomarkers reflecting both myocardial remodeling and function. In addition, we will test the effect of mirabegron on beige/brown fat activation and metabolism. Our proposal therefore combines a major conceptual advance and repurposing of an original drug to validate pre-clinical discoveries in the context of a major health problem.
Publication of trial rationale/design | Documents, reports | 2020-04-01 17:23:22 |
Abstracts presentation at heart failure meetings | Documents, reports | 2020-04-01 17:23:22 |
Functional website | Demonstrators, pilots, prototypes | 2020-04-01 17:23:22 |
Take a look to the deliverables list in detail: detailed list of BETA3_LVH deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2016 |
ESC On-going EU Projects published pages: , ISSN: , DOI: |
2020-04-01 | |
2018 |
Anne-Catherine Pouleur, Stefan Anker, Dulce Brito, Oana Brosteanu, Dirk Hasenclever, Barbara Casadei, Frank Edelmann, Gerasimos Filippatos, Damien Gruson, Ignatios Ikonomidis, Renaud Lhommel, Masliza Mahmod, Stefan Neubauer, Alexandre Persu, Bernhard L. Gerber, Stefan Piechnik, Burkert Pieske, Elisabeth Pieske-Kraigher, Fausto Pinto, Piotr Ponikowski, Michele Senni, Jean-Noël Trochu, Nancy Van Overstraeten, Rolf Wachter, Jean-Luc Balligand Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Be published pages: , ISSN: 2055-5822, DOI: 10.1002/ehf2.12306 |
ESC Heart Failure | 2020-04-01 |
2016 |
Lauriane Y. M. Michel, Jean-Luc Balligand New and Emerging Therapies and Targets: Beta-3 Agonists published pages: 205-223, ISSN: , DOI: 10.1007/164_2016_88 |
2020-04-01 | |
2018 |
S. Piechnik Piechnik Group: Myocardial functional T1 mapping – Advanced cardiac magnetic resonance imaging techniques published pages: , ISSN: , DOI: |
2020-04-01 | |
2015 |
Frédéric Soumois Une molécule pour soulager le coeur published pages: , ISSN: , DOI: |
Le Soir daily | 2020-04-01 |
2015 |
Jean-Luc Balligand Vers un nouveau traitement de l\'insuffisance cardiaque ? published pages: , ISSN: , DOI: |
2020-04-01 | |
2015 |
Nancy Van Overstraeten Towards a new treatment for cardiac remodeling ? published pages: , ISSN: , DOI: |
2020-04-01 | |
2015 |
EU A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease published pages: , ISSN: , DOI: |
2020-04-01 | |
2015 |
Nancy Van Overstraeten Youtube video published pages: , ISSN: , DOI: |
2020-04-01 | |
2015 |
Jean-Luc Balligand seminar published pages: , ISSN: , DOI: |
2020-04-01 | |
2015 |
Anne-Catherine Pouleur Seminar: Leçon publique sur l\'HFpEF published pages: , ISSN: , DOI: |
2020-04-01 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BETA3_LVH" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BETA3_LVH" are provided by the European Opendata Portal: CORDIS opendata.